8-Hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease

NeuroReport

Volumn 16, Issue 7, 2005, Pages 699-703

  Mignon, Laurence J ^a   Wolf, William A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HINES VA HOSPITAL   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

5 HTIA; Aspartate; Glutamate; In vivo microdialysis; Parkinson's disease; Serotonin; Striatum

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ASPARTIC ACID; DOPAMINE; EXCITATORY AMINO ACID; GLUTAMIC ACID; OXIDOPAMINE; SEROTONIN 1A AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DRUG EFFECT; LOCOMOTION; MALE; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ASPARTIC ACID; CORPUS STRIATUM; DENERVATION; DISEASE MODELS, ANIMAL; GLUTAMIC ACID; INJECTIONS, SUBCUTANEOUS; MALE; MICRODIALYSIS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN AGONISTS; SYMPATHOLYTICS;

EID: 20044376711     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200505120-00009     Document Type: Article

References (25)

1. Bellomo M, Giuffrida R, Palmeri A, Sapienza S. Excitatory amino acids as neurotransmitters of corticostriatal projections: immunocytochemical evidence in the rat. Arch Ital Biol 1998; 136:215-223.
2. Young AM, Bradford HF. Excitatory amino acid neurotransmitters in the corticostriate pathway: studies using intracerebral microdialysis in vivo. J Neurochem 1986; 47:1399-1404.
3. Yamamoto BK, Cooperman MA. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 1994; 14:4159-4166.
4. Yamamoto BK, Davy S. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J Neurochem 1992; 58:1736-1742.
5. Meshul CK, Emre N, Nakamura CM, Allen C, Donohue MK, Buckman JF. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 1999; 88:1-16.
6. Chase TN, Oh JD, Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J. Neurol 2000; 247(Suppl 2):1136-1142.
7. Elliott PJ, Close SP, Walsh DM, Hayes AG, Marriott AS. Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists. J Neural Transm Parkinson Dis Dement Sect 1990; 2:91-100.
8. Carlsson M, Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 1989; 75:221-226.
9. Boldry RC, Chase TN, Engber TM. Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions. J Pharmacol Exp Ther 1993; 267:1454-1459.
10. Dijk SN, Francis PT, Stratmann GC, Bowen DM. NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5-HT1A antagonist. Br J Pharmacol 1995; 115:1169-1174.
11. Matsuyama S, Nei K, Tanaka C. Regulation of glutamate release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus. Brain Res 1996; 728:175-180.
12. Semkova I, Wolz P, Krieglstein J. Neuroprotective effect of 5-HT1A receptor agonist, Bay X 3702, demonstrated in vitro and in vivo. Eur J Pharmacol 1998; 359:251-260.
13. Wadenberg ML. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 1996; 20:325-339.
14. Mignon L, Wolf WA. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology (Berl) 2002; 163:85-94.
15. Mignon LJ, Wolf WA. R-(+)-8-OHDPAT, a serotonin 5-HT1A agonist, induces ipsilateral turning in the unilateral 6-OHDA-lesioned rat. Soc Neurosci Abs 2002; 26:395.
16. Kehr J. Determination of glutamate and aspartate in microdialysis samples by reversed-phase column liquid chromatography with fluorescence and electrochemical detection. J Chromatogr B Biomed Sci Appl 1998; 708:27-38.
17. Anglade P, Mouatt-Prigent A, Agid Y, Hirsch E. Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration 1996; 5:121-128.
18. Lindefors N, Ungerstedt U. Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci Lett 1990; 115:248-252.
19. Mitchell IJ, Carroll CB. Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action. Neurosci Biobehav Rev 1997; 21: 469-475.
20. Wright DE, Seroogy KB, Lundgren KH, Davis BM, Jennes L. Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain. J Comp Neurol 1995; 351:357-373.
21. Francis PT, Pangalos MN, Pearson RC, Middlemiss DN, Stratmann GC, Bowen DM. 5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. J Pharmacol Exp Ther 1992; 261:1273-1281.
22. Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM. Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 1996; 14:35-46.
23. Araneda R, Andrade R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 1991; 40:399-412.
24. Tanaka E, North RA. Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J Neurophysiol 1993; 69:1749-1757.
25. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffman D, Benabid AL. Electrical stimulation of the subthalamic nucleus in advanced Parkinsons disease. N Engl J Med 1998; 339:1105-1111.